ITeos Announces 2024 Strategic Priorities and Anticipated Milestones; Cash Balance And Investment Balance Of $644.9M As Of September 30, 2023 Expected To Provide Runway Through 2026
ITeos Announces 2024 Strategic Priorities and Anticipated Milestones; Cash Balance And Investment Balance Of $644.9M As Of September 30, 2023 Expected To Provide Runway Through 2026
iTEOS宣布了2024年的战略优先事项和预期里程碑；截至2023年9月30日的现金余额和投资余额为6.449亿美元，预计将在2026年之前提供跑道
- - TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC
- - Adenosine portfolio clinical data readouts anticipated in second half of 2024, including inupadenant's Phase 2 A2A-005 and EOS-984's Phase 1 trial
- - EOS-984 preclinical data demonstrating novel mechanism of action in the adenosine pathway anticipated in second quarter of 2024
- -预计将于2024年公布TIGIT计划的临床数据，包括两项评估belrestotug + dostarlimab在1L NSCLC和1L HNSCC中的2期试验
- -预计将于 2024 年下半年公布腺苷组合临床数据，包括 inupadenant 的 2 期 A2A-005 和 EOS-984 的 1 期试验
- -EOS-984 临床前数据显示腺苷通路的新作用机制预计将在 2024 年第二季度推出